Related Experiment Video

Updated: Aug 29, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K

[Pharmaceutical therapy of infarct-related cardiogenic shock]

Raphael R Bruno, Malte Kelm, Christian Jung

    Deutsche Medizinische Wochenschrift (1946)
    |September 7, 2022
    PubMed

    Insights

    Cardiogenic shock complicating acute myocardial infarction requires immediate revascularization. Subsequent therapy for persistent shock involves hemodynamic phenotyping and targeted pharmacological interventions, including vasopressors and inotropes.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Intensive Care Medicine

    Background:

    • Acute myocardial infarction with cardiogenic shock (AMI-CS) is a rare but critical condition.
    • The definition of cardiogenic shock lacks uniformity, complicating treatment protocols.
    • Immediate revascularization is crucial for improving prognosis in AMI-CS patients.

    Purpose of the Study:

    • To provide an updated overview of pharmacological treatment options for AMI-CS.
    • To guide personalized therapy based on hemodynamic phenotyping.
    • To clarify indications for specific medications in managing AMI-CS.

    Main Methods:

    • Review of current literature on pharmacological management of AMI-CS.
    • Analysis of treatment guidelines and clinical recommendations.
    • Discussion of hemodynamic phenotyping for personalized therapy.

    Main Results:

    • Antiplatelet medication is fundamental for myocardial reperfusion.
    • Norepinephrine is the first-line vasopressor for hypotension.
    • Dobutamine or calcium sensitizers like levosimendan are recommended for inotropy.

    Conclusions:

    • Hemodynamic phenotyping is essential for guiding therapy in patients with persistent shock post-revascularization.
    • Specific pharmacological agents have defined roles, with some (e.g., dopamine) no longer recommended.
    • This review offers a detailed guide to current pharmacological strategies in AMI-CS.

    More Related Videos

    The Intra-Aortic Balloon Pump06:13

    The Intra-Aortic Balloon Pump

    Published on: February 5, 2021

    21.9K
    Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model07:20

    Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

    Published on: February 10, 2023

    1.3K

    Related Concept Videos

    Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

    Cardiopulmonary Resuscitation IV: Pharmacological Management

    Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
    65
    Acute Coronary Syndrome IV: Interprofessional Care01:28

    Acute Coronary Syndrome IV: Interprofessional Care

    IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
    22
    Myocarditis III: Medical Management01:14

    Myocarditis III: Medical Management

    Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
    13
    Blood Pressure Imbalances and Circulatory Shock01:24

    Blood Pressure Imbalances and Circulatory Shock

    Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
    Blood Pressure: Hypertension and Hypotension
    Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
    975
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    24
    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    692